CN107998313A - 一种治疗痛风病的中药酵素及其制备方法 - Google Patents
一种治疗痛风病的中药酵素及其制备方法 Download PDFInfo
- Publication number
- CN107998313A CN107998313A CN201810024189.6A CN201810024189A CN107998313A CN 107998313 A CN107998313 A CN 107998313A CN 201810024189 A CN201810024189 A CN 201810024189A CN 107998313 A CN107998313 A CN 107998313A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- chinese medicine
- ferment
- enzymolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 129
- 241000283707 Capra Species 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 138
- 241000894006 Bacteria Species 0.000 claims abstract description 126
- 239000000463 material Substances 0.000 claims abstract description 38
- 241000235342 Saccharomycetes Species 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 19
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 19
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 18
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 18
- 241000522190 Desmodium Species 0.000 claims abstract description 18
- 241000427159 Achyranthes Species 0.000 claims abstract description 17
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 17
- 241000601164 Clematis orientalis Species 0.000 claims abstract description 17
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 17
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 16
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 16
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 16
- 239000004863 Frankincense Substances 0.000 claims abstract description 16
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 16
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 16
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 15
- 241000605422 Asparagus asparagoides Species 0.000 claims abstract description 14
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 14
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 14
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 4
- 239000007788 liquid Substances 0.000 claims description 58
- 239000000843 powder Substances 0.000 claims description 52
- 238000000855 fermentation Methods 0.000 claims description 40
- 230000004151 fermentation Effects 0.000 claims description 40
- 102000004190 Enzymes Human genes 0.000 claims description 37
- 108090000790 Enzymes Proteins 0.000 claims description 37
- 229940088598 enzyme Drugs 0.000 claims description 37
- 239000012530 fluid Substances 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 31
- 210000003734 kidney Anatomy 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000002137 ultrasound extraction Methods 0.000 claims description 21
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000004659 sterilization and disinfection Methods 0.000 claims description 17
- 241000218176 Corydalis Species 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 11
- 239000007640 basal medium Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 11
- 238000011081 inoculation Methods 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 11
- 235000015097 nutrients Nutrition 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 210000003127 knee Anatomy 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 150000003384 small molecules Chemical class 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 abstract description 2
- 210000000664 rectum Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 39
- 230000000694 effects Effects 0.000 description 29
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 26
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 25
- 229940116269 uric acid Drugs 0.000 description 25
- 241000700159 Rattus Species 0.000 description 16
- 241001122767 Theaceae Species 0.000 description 13
- 201000005569 Gout Diseases 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 240000005561 Musa balbisiana Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000010985 leather Substances 0.000 description 4
- 229950000193 oteracil Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 3
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000005739 Eurycoma longifolia Species 0.000 description 2
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- OJISWUQNQQWEND-FCVLBCLDSA-N Paederoside Chemical group O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)SC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OJISWUQNQQWEND-FCVLBCLDSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000256856 Vespidae Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- -1 alkene lactone Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960002708 antigout preparations Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000796 barbital sodium Drugs 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 2
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000000031 Achyranthes bidentata Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241001656831 Arctous alpina Species 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000522254 Cassia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 241001256368 Clematis chinensis Species 0.000 description 1
- 241001503987 Clematis vitalba Species 0.000 description 1
- 235000012469 Cleome gynandra Nutrition 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000092728 Eleutherococcus gracilistylus Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 235000014043 Glechoma hederacea var parviflora Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000720991 Illicium Species 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 241001571764 Lysimachia christinae Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 244000215554 Nepeta hederacea Species 0.000 description 1
- 241000567232 Ochnaceae Species 0.000 description 1
- 241000123069 Ocyurus chrysurus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000005859 Orthosiphon aristatus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 244000038594 Phyllanthus urinaria Species 0.000 description 1
- VUGRLRAUZWGZJP-UHFFFAOYSA-N Plantaginin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-UHFFFAOYSA-N 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- SNFFBROYEDWRGB-SASFBZJPSA-N Plantagoside Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)c(O)cc([C@H]2Oc3c(c(O)cc(O)c3)C(=O)C2)c1 SNFFBROYEDWRGB-SASFBZJPSA-N 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 240000003085 Quassia amara Species 0.000 description 1
- 235000009694 Quassia amara Nutrition 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 240000006688 Telosma cordata Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- IBIPGYWNOBGEMH-DILZHRMZSA-N asperuloside Chemical compound O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBIPGYWNOBGEMH-DILZHRMZSA-N 0.000 description 1
- COUXBBBIXWWAEP-AGUBZPQCSA-N asperuloside Natural products CC(=O)OCC1=C[C@@H]2OC(=O)C3=CO[C@@H](OC[C@H]4O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H]1[C@H]23 COUXBBBIXWWAEP-AGUBZPQCSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- VUGRLRAUZWGZJP-IAAKTDFRSA-N plantaginin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-IAAKTDFRSA-N 0.000 description 1
- SNFFBROYEDWRGB-NHXQFOETSA-N plantagoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC([C@H]2OC3=CC(O)=CC(O)=C3C(=O)C2)=CC(O)=C1O SNFFBROYEDWRGB-NHXQFOETSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940013788 quassia Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000001751 uricolytic effect Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素,所述中药原料包括:东革阿里、薏苡仁、黄柏、牛膝、苍术、威灵仙、车前子、川芎、珠子草、桂枝8‑15重量份、红花、鸡矢藤、丹参、土茯苓、金钱草、五加皮、乳香、千年健份、没药、连翘;所述复合菌包括浓度为1.0×108~2.5×108CFU/mL的酵母菌和浓度为2.0×108~3.2×108CFU/mL的醋酸菌。本发明还公开了一种治疗痛风病的中药酵素的制备方法。本发明通过引入多菌共生技术,对多种中药发酵后制成中药酵素,改进治疗直肠的中药的用药方式,得到小分子中药酵素,降低中药对肠胃的刺激作用、提高中药中有益成分的吸收率。
Description
技术领域
本发明属于生物酶制剂技术领域,具体涉及一种治疗痛风病的中药酵素及其制备方法。
背景技术
痛风是嘌呤代谢紊乱致尿酸生成增多和/或尿酸排泄减少所引起的一组疾病。人之所以发生痛风是人类缺乏尿酸分解酶的结果。人由于缺乏将尿酸再分解的分解酶,故不可能将尿酸氧化成可溶解的尿囊素,嘌呤分解代谢的最终产物是尿酸,他是一种在体液中溶解度极低的的化合物。当嚓吟代谢发生紊乱时,就必然会导致尿酸生成过多,从而引起高尿酸血症,而痛风发病的先决条件是高尿酸血症。痛风的一切临床表现,皆由其钠盐从超饱和的细胞外液析出并沉积于组织引起。目前公认急性痛风性关节炎的发作是由于尿酸浓度过高,并超过了尿酸的溶解度而呈过和状态,致使尿酸钠微晶体在软骨、关节滑膜及周围组织沉淀而引起的非特异性炎症反应。通风病的主要危害是痛风性关节炎反复发作、痛风石形成引起关节破坏,丧失功能活动,严重时可造成残疾并引发肾脏损害,痛风还常伴腹型肥胖、高脂血症、高血压、2型糖尿病及心血管病等表现。。近些年来,痛风的发病率不断升高,并出现年轻化趋势而治疗方面并未有较大突破。
在临床治疗上,西医常用的药物有秋水仙碱、非甾体类抗炎药、糖皮质激素和促肾上腺皮质激素和抑制剂等,由于这些药物的不良反应多,临床使用受到限制。中医中药因其辨证论治、灵活多变、副作用小等特点在痛风治疗上显示出较大优势并取得良好效果;目前许多学者致力于中药治疗痛风的药效研究,以期寻求高效低毒的抗痛风药物。传统的中药大多是采用汤药或颗粒制剂等形式,传统的药剂方式导致中药利用率低、中药苦口、气味难闻、农药残留等弊端。
发明内容
为了克服现有技术的不足,本发明的目的在于提供一种治疗痛风病的中药酵素,通过引入多菌共生技术,对多种中药发酵后制成中药酵素,改进治疗痛风病中药的用药方式,得到小分子中药酵素,改善中药的口感、降低中药对肠胃的刺激作用、提高中药中有益成分的吸收率。
为解决上述问题,本发明所采用的技术方案如下:
一种治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素;
所述中药原料包括:东革阿里3-10重量份、薏苡仁15~30重量份、黄柏8-15重量份、牛膝5-15重量份、苍术10-20重量份、威灵仙5-15重量份、车前子15-30重量份、川芎12-20重量份、珠子草10-20重量份、桂枝8-15重量份、红花5-15重量份、鸡矢藤10-25重量份、丹参12-25重量份、土茯苓15-30重量份、金钱草10-25重量份、五加皮10-20重量份、乳香5-15重量份、千年健8-15重量份、没药5-15重量份、连翘5-15重量份;
所述复合菌包括浓度为1.0×108~2.5×108CFU/mL的酵母菌和浓度为2.0×108~3.2×108CFU/mL的醋酸菌。
作为进一步的方案,本发明所述的中药原料还包括追地风8~18重量份、延胡索5-15重量份、肾茶8-15重量份。
作为进一步的方案,本发明所述的东革阿里为红东革阿里、黄东革阿里、黑东革阿里中的一种或两种以上混合。
作为进一步的方案,本发明所述的中药原料包括:东革阿里5-8重量份、薏苡仁20~25重量份、黄柏10-15重量份、牛膝8-12重量份、苍术12-18重量份、威灵仙8-12重量份、车前子18-25重量份、川芎15-18重量份、珠子草12-18重量份、桂枝10-12重量份、红花8-12重量份、鸡矢藤15-20重量份、丹参15-20重量份、土茯苓20-25重量份、金钱草15-20重量份、五加皮12-18重量份、乳香8-12重量份、千年健10-15重量份、没药8-12重量份、连翘8-12重量份、追地风10~15重量份、延胡索8-12重量份、肾茶10-15重量份。
作为进一步的方案,本发明所述的中药原料包括:红东革阿里5重量份、黑东革阿里5份、薏苡仁22重量份、黄柏12重量份、牛膝10重量份、苍术15重量份、威灵仙10重量份、车前子20重量份、川芎15重量份、珠子草15重量份、桂枝10重量份、红花10重量份、鸡矢藤18重量份、丹参18重量份、土茯苓22重量份、金钱草18重量份、五加皮15重量份、乳香10重量份、千年健12重量份、没药10重量份、连翘10重量份、追地风12重量份、延胡索10重量份、肾茶12重量份。
作为进一步的方案,本发明所述的复合菌还包括浓度为1.2×108~2.5×108CFU/mL乳酸菌。
本发明的另一目的在于提供一种治疗痛风病的中药酵素的制备方法,通过该方法获得口感好、胃肠刺激作用小的中药酵素。具体方案如下。
一种治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,然后将每种中药粉末单独用超声萃取,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2-3天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1-2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为30-37%,在浓缩后的酶解液接种1.2-2.0%的酵母菌和1.0-1.2%醋酸菌后先在20-25℃温度下摇床发酵,然后在28-30℃温度下静置发酵,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为15-22%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
作为进一步的方案,本发明所述的超声萃取步骤中,采用20kHz的低频超声萃取8-12分钟,所述中药粉末与水的料液比为1:(100-400)。
作为进一步的方案,本发明所述的酶解步骤中,采用的复合酶的加酶量为100-150μg/g,所述复合酶是质量比为1:1:(2-5)的果胶酶、蛋白酶、纤维素酶;酶解的时间为8-12小时,酶解的温度控制在45-52℃,酶解液的pH值为5.5-5.8。
一种治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,然后在每种中药粉末单独用超声萃取,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2-3天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1-2天,经过2次继代培养,菌液待用;乳酸菌接种于MRS培养基在温度37℃下活化l-2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为30-37%,在浓缩后的酶解液接种1.2-2.0%的酵母菌、1.0-1.2%醋酸菌、1.2-1.5%乳酸菌后先在20-25℃温度下摇床发酵,然后在28-30℃温度下静置发酵,最后在35-40℃温度下继续发酵得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为15-22%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
相比现有技术,本发明的有益效果在于:
1.本发明所述的中药酵素,改进治疗痛风病中药的用药方式,得到小分子中药酵素,改善了传统中药苦涩的口感,降低中药对肠胃的刺激作用、提高了中药中有益成分的吸收率;
2.本发明所述的中药酵素,用于治疗或防止痛风病,同时相对于西药具有成本低、副作用小、易吸收等优点;
3.本发明所述的中药酵素也可以联合治疗痛风病的西药用药。
下面结合具体实施方式对本发明作进一步详细说明。
具体实施方式
本发明所述的治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素;
所述中药原料包括:东革阿里3-10重量份、薏苡仁15~30重量份、黄柏8-15重量份、牛膝5-15重量份、苍术10-20重量份、威灵仙5-15重量份、车前子15-30重量份、川芎12-20重量份、珠子草10-20重量份、桂枝8-15重量份、红花5-15重量份、鸡矢藤10-25重量份、丹参12-25重量份、土茯苓15-30重量份、金钱草10-25重量份、五加皮10-20重量份、乳香5-15重量份、千年健8-15重量份、没药5-15重量份、连翘5-15重量份;
所述复合菌包括浓度为1.0×108~2.5×108CFU/mL的酵母菌和浓度为2.0×108~3.2×108CFU/mL的醋酸菌。
作为进一步的方案,本发明所述的中药原料还包括追地风8~18重量份、延胡索5-15重量份、肾茶8-15重量份。
在本发明中,所采用的东革阿里(Eurycoma longifolia)又名Tongkat Ali,为苦木科野生灌木植物,主要分布于东南亚,性凉,味苦,具有强肾、促进生育、抗癌、治疗前列腺炎、退热和抗疟疾等功效;是马来西亚的民间用药历史显示东革阿里具有较好的治疗痛风作用;研究发现东革阿里提取物可降低尿酸钠诱致的大鼠痛风性关节炎模型的大鼠痛感。薏苡仁富含淀粉、蛋白质、多种维生素及人体所需的多种氨基酸,从薏苡仁热提取物分得的中性多糖葡聚糖混合物及酸性多糖均具有示抗补体活性。黄柏水浸液对二甲苯所致的鼠肿胀有明显的抗炎作用,而且在健康豚鼠化腐生肌实验中发现,黄柏冷敷剂对金黄色葡萄球菌感染的破脶皮肤也有明显的抗炎作用;研究发现,黄柏及其不同炮制品均能明显降低高尿酸血症模型大鼠的尿酸和肌酐水平,并能抑制急性痛风关节炎模型大鼠的关节肿胀。苍术中的有效成分芹烷二烯酮、苍术烯内酯Ⅰ有毛细管透过性亢进的抑制作用和抗炎作用,苍术烯内酯Ⅱ、Ⅲ也具有抗炎活性。牛膝,别名:牛磕膝,(Achyranthes bidentata Blume.)苋科、牛膝属多年生草本,根入药,生用,活血通经;治产后腹痛,月经不调,闭经,鼻衄,虚火牙痛,脚气水肿;熟用,补肝肾,强腰膝;治腰膝酸痛,肝肾亏虚,跌打瘀痛;现代医学研究发现牛膝不同炮制品均具有镇痛抗炎作用。威灵仙(学名Clematis chinensis Osbeck)是毛茛科,铁线莲属多年生木质藤本,其根及茎入药具有祛风湿、通经络、消骨梗之功效;威灵仙中的总皂苷具有显著降低动物血清尿酸水平的作用,可用于制备抗高尿酸血症及痛风的药物。车前子的种子含多量黏液、车前子酸(Planterolic acid)、车前子甙(Plantaginin)、车前烯醇酸(Plantenolic acid)、琥珀酸(Succinic acid)、腺嘌呤(Adenine或6-Aminopurine)、胆碱(Choline)、梓醇(Catalpol)、蛋白质及各种脂肪酸(棕榈酸、硬脂酸、花生酸、油酸、亚油酸、亚麻酸等),黏液中含酸性黏多糖车前聚糖(Plantasan),车前子能使水分、氯化钠、尿素及尿酸排出增多而有利尿作用,研究发现车前草有促使家兔关节囊滑膜结缔组织增生作用,从而使松弛了的关节囊恢复原有的紧张度。川芎(学名:Ligusticumchuanxiong hort),常用于活血行气,祛风止痛。珠子草拉丁学名:Phyllanthus niruriLinn.属名:叶下珠属科名:大戟科俗名别名:蛇仔草,珠子草额提取物对氧嗪酸钾及尿酸诱导的高尿酸血症大鼠有显著的降血尿酸作用,进一步研究其降血尿酸作用主要是通过促进尿酸排泄,抑制黄嘌呤氧化酶活性这两个途径实现的。桂枝是肉桂的干燥嫩枝,桂枝辛温,可祛风寒;桂枝能发汗解表,温经通脉,助阳化气,散寒止痛。红花,(拉丁学名:Carthamustinctorius L.),别名:红蓝花、刺红花,菊科、红花属植物,有活血化瘀,散湿去肿的功效。鸡矢藤,又名鸡屎藤,为茜草科植物鸡矢藤的全草,夏季采收全草,晒干。其味甘、微苦,性平;具有祛风利湿,止痛解毒,消食化积,活血消肿之功效;用于风湿筋骨痛,跌打损伤,外伤性疼痛;其主要活性成份为鸡矢藤苷、鸡矢藤次苷、车叶草苷、γ-谷甾醇及挥发油等;现代中研究发现鸡矢藤可有效保护滑膜组织的炎性损伤而到抗痛风的作用。丹参,为唇形科植物丹参Salvia miltiorrhiza Bge.的干燥根和根茎,具有活血祛瘀,通经止痛,清心除烦,凉血消痈之功效;丹参根部提取出紫草酸,体外实验证实该成分可抑制黄嘌呤氧化酶活性,并且对氧嗓酸盐引起的尿酸升高及尿酸盐引起的大鼠足垫肿胀具有治疗作用。金钱草,别名:过路黄、镜面草、翠屏草、荷苞草、肉馄饨草、金锁匙、连钱草、对座草、叶金钱草、钱叶草,钱芊金等,有清热利尿、祛风止痛、止血生肌、消炎解毒、杀虫之功;金钱草水提取物给予高尿酸血症模型小鼠给药,结果表明金钱草水提物对高尿酸血症小鼠具有降低血清尿酸水平的作用。五加皮为五加科植物细柱五加的干燥根皮有祛风湿,补益肝肾,强筋壮骨,利水消肿的作用。乳香,为橄榄科植物乳香树同属植物树皮渗出的树脂,活血行气止痛,消肿生肌之功效。肾茶,又名猫须草、猫须公、苞须花,“牙努秒”,属于唇形科肾茶属,多年生草本;全草含三萜类,甾醇类,黄酮类,其中肾茶所含的主要活性成分为迷迭香酸、熊果酸、黄酮类及肌醇等,其抗炎的特效成分为迷迭香酸;研究发现,肾茶的抗炎作用主要与迷迭香酸和熊果酸成分有关,肾茶具有明显的抗炎作用,抗炎机制可能与抑制花生四烯酸代谢中的5-脂氧酶和对补体依赖性PGI的合成有抑制作用相关;猫须草中含丰富的多酚,可提高车前子提取物的亲水性,从而提高利尿和排尿酸的作用。千年键,为天南星科植物,有祛风湿,壮筋骨的功效。没药为橄榄科植物地丁树的干燥树脂,具有散瘀定痛,消肿生肌之功效。连翘是木樨科连翘属植物,具有清心解热,消肿散结,利尿等功效。追地风又名桐叶藤、利筋藤、地风皮,是木兰科八角属常绿灌木,具有祛风除湿,行气止痛之功效。在本发明中,通过上述多种中药配伍,其功能之间存在相互协同增效的作用。
在本发明中所采用的东革阿里为红东革阿里、黄东革阿里、黑东革阿里中的一种或两种以上混合。黄东革阿里入脾胃和补益之功效;黑东革阿里又名野山黑金刚,红东革阿里和黑东革阿里均具有可补中益神、壮阳、助肾强、利尿、治水肿的功效,对腰腿疼痛、关节炎、体弱乏力者效果显著。这三者中其中数黑东革阿里的功效最为显著。因此在本发明中选择黑东革阿里与黄东革阿里或红东革阿里混合使用效果最佳。
作为进一步的方案,本发明所述的中药原料包括:东革阿里5-8重量份、薏苡仁20~25重量份、黄柏10-15重量份、牛膝8-12重量份、苍术12-18重量份、威灵仙8-12重量份、车前子18-25重量份、川芎15-18重量份、珠子草12-18重量份、桂枝10-12重量份、红花8-12重量份、鸡矢藤15-20重量份、丹参15-20重量份、土茯苓20-25重量份、金钱草15-20重量份、五加皮12-18重量份、乳香8-12重量份、千年健10-15重量份、没药8-12重量份、连翘8-12重量份、追地风10~15重量份、延胡索8-12重量份、肾茶10-15重量份。
作为进一步的方案,本发明所述的中药原料包括:红东革阿里5重量份、黑东革阿里5份、薏苡仁22重量份、黄柏12重量份、牛膝10重量份、苍术15重量份、威灵仙10重量份、车前子20重量份、川芎15重量份、珠子草15重量份、桂枝10重量份、红花10重量份、鸡矢藤18重量份、丹参18重量份、土茯苓22重量份、金钱草18重量份、五加皮15重量份、乳香10重量份、千年健12重量份、没药10重量份、连翘10重量份、追地风12重量份、延胡索10重量份、肾茶12重量份。
作为进一步的方案,本发明所述的复合菌还包括浓度为1.2×108~2.0×108CFU/mL乳酸菌。
本发明的另一目的在于提供一种治疗痛风病的中药酵素的制备方法,通过该方法获得口感好、胃肠刺激作用小的中药酵素。具体方案如下。
一种治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,然后将每种中药粉末单独用超声萃取,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2-3天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1-2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为30-37%,在浓缩后的酶解液接种1.2-2.0%的酵母菌和1.0-1.2%醋酸菌后先在20-25℃温度下摇床发酵,然后在28-30℃温度下静置发酵,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为15-22%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
作为进一步的方案,本发明所述的超声萃取步骤中,采用20kHz的低频超声萃取8-12分钟,所述中药粉末与水的料液比为1:(100-400)。优选的,料液比为1:300。
作为进一步的方案,本发明所述的酶解步骤中,采用的复合酶的加酶量为100-150μg/g,所述复合酶是质量比为1:1:(2-5)的果胶酶、蛋白酶、纤维素酶;酶解的时间为8-12小时,酶解的温度控制在45-52℃,酶解液的pH值为5.5-5.8。
一种治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,然后在每种中药粉末单独用超声萃取,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2-3天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1-2天,经过2次继代培养,菌液待用;乳酸菌接种于MRS培养基在温度37℃下活化l-2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为30-37%,在浓缩后的酶解液接种1.2-2.0%的酵母菌、1.0-1.2%醋酸菌、1.2-1.5%乳酸菌后先在20-25℃温度下摇床发酵,然后在28-30℃温度下静置发酵,最后在35-40℃温度下继续发酵得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为15-22%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
本发明中,采用复合的乳酸菌进行发酵,由于酵母菌和醋酸菌共生发酵时,先于20℃条件下酵母菌成为优势菌,使得酵液中的酶活性和总酸含量上升,但酵母菌活菌数达到饱和程度时,酵母菌因营养物质消耗受到限制不能继续扩增;当温度转到25℃时,醋酸菌大量繁殖,醋酸菌利用糖源或酵母菌代谢产物继续发酵产生大量有机酸,间接的使发酵液的总酸含量较单菌发酵要高,这样利于酵液的发酵。作为进一步的方案,本发明所述的复合菌还包括浓度为1.2×108~2.5×108CFU/mL乳酸菌。乳酸菌是在37℃是开始大量繁殖,可以有效持续发酵液的发酵过程。
本发明采用复合菌进行发酵,随着发酵天数增加,酵母菌活菌数增加,代谢产物增加,为乳酸菌提供氨基酸、维生素和丙酮酸盐等营养因子,由于两种菌种协同发酵,相互促进了生长。因此,在本发明中酵母菌的发酵时间为6-8天,醋酸菌的发酵时间为8-10天最佳发酵时间。
以下是本发明具体的实施方式,在下述实施例中所采用的原料、试剂以及设备均可以通过商业方式获得。
实施例1
一种治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素;
所述中药原料包括:东革阿里3重量份、薏苡仁15重量份、黄柏8重量份、牛膝5重量份、苍术10重量份、威灵仙5重量份、车前子15重量份、川芎12重量份、珠子草10重量份、桂枝8重量份、红花5重量份、鸡矢藤10重量份、丹参12重量份、土茯苓15重量份、金钱草10重量份、五加皮10重量份、乳香5重量份、千年健8重量份、没药5重量份、连翘5重量份;
所述复合菌包括浓度为1.0×108CFU/mL的酵母菌和浓度为2.0×108CFU/mL的醋酸菌;
治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,中药粉末与水的料液比为1:100-400,然后将每种中药粉末单独用20kHz的低频超声萃取8分钟,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液,复合酶的加酶量为100μg/g,所述复合酶是质量比为1:1:2的果胶酶、蛋白酶、纤维素酶;酶解的时间为8小时,酶解的温度控制在52℃,酶解液的pH值为5.5;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为30%,在浓缩后的酶解液接种1.2%的酵母菌和1.0%醋酸菌后先在20℃温度下摇床发酵,然后在28℃温度下静置发酵,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为15%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。实施例2
一种治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素;
所述中药原料包括:东革阿里10重量份、薏苡仁30重量份、黄柏15重量份、牛膝15重量份、苍术10重量份、威灵仙15重量份、车前子30重量份、川芎20重量份、珠子草20重量份、桂枝15重量份、红花15重量份、鸡矢藤25重量份、丹参25重量份、土茯苓30重量份、金钱草25重量份、五加皮20重量份、乳香15重量份、千年健15重量份、没药15重量份、连翘15重量份;
所述复合菌包括浓度为1.2×108CFU/mL的酵母菌和浓度为2.0×108CFU/mL的醋酸菌;
治疗痛风病的中药酵素的制备方法,包括
治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,中药粉末与水的料液比为1:200,然后将每种中药粉末单独用20kHz的低频超声萃取12分钟,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液,复合酶的加酶量为150μg/g,所述复合酶是质量比为1:1:5的果胶酶、蛋白酶、纤维素酶;酶解的时间为12小时,酶解的温度控制在45℃,酶解液的pH值为5.5;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养3天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为37%,在浓缩后的酶解液接种2.0%的酵母菌和1.2%醋酸菌后先在25℃温度下摇床发酵,然后在30℃温度下静置发酵,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为22%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
实施例3
一种治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素;
所述的中药原料包括:东革阿里5重量份、薏苡仁20重量份、黄柏10重量份、牛膝8重量份、苍术12重量份、威灵仙8重量份、车前子18重量份、川芎15重量份、珠子草12重量份、桂枝10重量份、红花8重量份、鸡矢藤15重量份、丹参15重量份、土茯苓20重量份、金钱草15重量份、五加皮12重量份、乳香8重量份、千年健10重量份、没药8重量份、连翘8重量份、追地风10重量份、延胡索8重量份、肾茶10重量份。所述复合菌包括浓度为2.2×108CFU/mL的酵母菌、浓度为2.5×108CFU/mL的醋酸菌以及1.2×108CFU/mL乳酸菌;
治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,中药粉末与水的料液比为1:300,然后将每种中药粉末单独用20kHz的低频超声萃取10分钟,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液,复合酶的加酶量为120μg/g,所述复合酶是质量比为1:1:3的果胶酶、蛋白酶、纤维素酶;酶解的时间为10小时,酶解的温度控制在47℃,酶解液的pH值为5.5;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为35%,在浓缩后的酶解液接种1.2-2.0%的酵母菌和1.0-1.2%醋酸菌后先在22℃温度下摇床发酵,然后在28℃温度下静置发酵,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为20%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
实施例4
一种治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素;所述的中药原料包括:东革阿里8重量份、薏苡仁25重量份、黄柏15重量份、牛膝12重量份、苍术18重量份、威灵仙12重量份、车前子25重量份、川芎18重量份、珠子草18重量份、桂枝12重量份、红花12重量份、鸡矢藤20重量份、丹参20重量份、土茯苓25重量份、金钱草20重量份、五加皮18重量份、乳香12重量份、千年健15重量份、没药12重量份、连翘12重量份、追地风15重量份、延胡索12重量份、肾茶15重量份;
所述复合菌包括浓度为2.5×108CFU/mL的酵母菌、浓度为2.8×108CFU/mL的醋酸菌以及2.0×108CFU/mL乳酸菌;
治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,中药粉末与水的料液比为1:350,然后将每种中药粉末单独用20kHz的低频超声萃取10分钟,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液,复合酶的加酶量为100-150μg/g,所述复合酶是质量比为1:1:4的果胶酶、蛋白酶、纤维素酶;酶解的时间为9小时,酶解的温度控制在50℃,酶解液的pH值为5.8;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为32%,在浓缩后的酶解液接种1.5%的酵母菌和1.5%醋酸菌后先在25℃温度下摇床发酵,然后在30℃温度下静置发酵,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为20%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
实施例5
一种治疗痛风病的中药酵素,是由中药原料经复合菌发酵制成的酵素;
所述的中药原料包括:红东革阿里5重量份、黑东革阿里5份、薏苡仁22重量份、黄柏12重量份、牛膝10重量份、苍术15重量份、威灵仙10重量份、车前子20重量份、川芎15重量份、珠子草15重量份、桂枝10重量份、红花10重量份、鸡矢藤18重量份、丹参18重量份、土茯苓22重量份、金钱草18重量份、五加皮15重量份、乳香10重量份、千年健12重量份、没药10重量份、连翘10重量份、追地风12重量份、延胡索10重量份、肾茶12重量份;
所述复合菌包括浓度为2.0×108CFU/mL的酵母菌和浓度为3.2×108CFU/mL的醋酸菌;
治疗痛风病的中药酵素的制备方法,包括
超声萃取步骤:按照比例将上述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,药粉末与水的料液比为1:400,然后在每种中药粉末单独采用20kHz的低频超声萃取10分钟,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为35%,在浓缩后的酶解液接种1.5%的酵母菌和1.0%醋酸菌后先在22℃温度下摇床发酵8天,然后在30℃温度下静置发酵8天,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为20%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
效果评价
1.急毒性试验
1)小鼠口服急毒性试验:选取60只小鼠,雌雄各半,在人工照明12h、通风良好的条件下饲养观察3d后,随机分成5个试验组(对应实施例1-5)和1个对照组,每组10只,给药前24h和给药后4h内禁食,但不禁水。口服按0.2mL/20g剂量灌胃给药;连续观察10d,记录小鼠中毒症状,小鼠死亡或试验结束后进行剖解,观察各组织器官的变化,取心脏、肝脏、脾脏、肾脏、肺脏及肠组织做病理切片,并计算半数致死量(LD50)。
结果显示:用灌胃针经口腔灌入复方苦木注射液后,个别小鼠蜷缩在角落,活动减少,但第3d观察,发现有38只小鼠活动、饮水和采食恢复正常;连续观察10天后,50只小鼠均健康存活,且全部小鼠的精神、食欲、肤色、分泌物、呼吸、食欲、肌肉运动等方面均未观察到异常变化。试验结束后剖检,发现各试验组小鼠脏器变化与对照组无明显眼观差异。按照毒理学安全性评价标准得知,LD50>10000mg/kg,属无毒性物质。
2.药效试验
试验材料:SPF级雄性SD大鼠60只,体质量(200±20),购自广州中医药大学实验动物中心,实验动物饲养于暨南大学实验动物中心SPF级实验室,室温(20±2),相对湿度40-70%,给予灭菌清洁饮水、饲料;笼具、垫料均经高温高压灭菌处理;尿酸、肌酐、尿素氮、黄嘌呤氧化酶、腺苷脱氨酶及考马斯亮蓝试剂盒均购自南京建成生物工程研究所;氧嗪酸钾购自山东中科泰斗化学有限公司;羧甲基纤维素钠购自上海赛璐珞厂;别嘌醇片购自广东彼迪药业有限公司;戊巴比妥钠,购自德国merck公司。
试验方法:SPF级雄性SD大鼠除正常对照组10只外,造模组大鼠(50只)按10mL/kg灌胃给予氧嗪酸钾2g/(kg.d)构建高尿酸血症模型,正常对照组大鼠灌胃等体积溶媒,连续10后,腹腔注射3%戊巴比妥钠麻醉大鼠,眼眶后静脉丛采血(0.5mL),以4℃、3000r/min离心15min,取上层血清用钨酸法测定血清尿酸含量,将尿酸含量高于110μmol/L的大鼠确定为造模成功。
将造模成功的大鼠按血清尿酸含量均衡原则分为模型组、别嘌醇(25mg/kg)阳性对照组及给实施例1-5中药酵素的给药组1-5,分别对应实施例1-5的中药酵素,每组10只,除对照组外,给眼组各组动物每天上午灌胃氧嗪酸钾(2g/kg)维持模型,下午按10mL/kg灌胃给予受试药物,对照组与给药组大鼠给予等体积蒸馏水,连续处理7、14天后3%巴比妥钠(30mg/kg)腹腔注射麻醉,眼眶后静脉丛取血(0.5mL),4℃、3000r/min离心15min,取上层血清采用钨酸法并严格按试剂盒说明书操作测定血清尿酸含量;药物处理21d后,3%巴比妥钠(30mg/kg)麻醉,后腹腔动脉取血%0G,测定血清尿酸水平(取适量0.2-1g肝脏组织,加入9倍体积生理盐水,用眼科剪快速剪碎组织块(冰上操作),组织匀浆机制作10%肝匀浆,考马斯亮蓝蛋白定量,检测肝匀浆和血清中黄嘌呤氧化酶和腺苷脱氨酶的含量;大鼠肾脏经4%多聚甲醛固定,石蜡包埋,切片,脱水,苏木素染色,镜检拍片,显微镜下观察大鼠肾脏组织病理学变化。实验结果均以表示,采用SPP16.0统计软件进行数据处理,以p<0.05为差异有统计学意义。实验结果参见下表1。
表1:实施例1-5的中药酵素对大鼠血清尿酸含量的影响
表1结果显示:与对照组比较,给药组组大鼠在给药后各时间点血清尿酸含量均显著降低(p<0.01)。
上述实施方式仅为本发明的优选实施方式,不能以此来限定本发明保护的范围,本领域的技术人员在本发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
Claims (10)
1.一种治疗痛风病的中药酵素,其特征在于,是由中药原料经复合菌发酵制成的酵素;
所述中药原料包括:东革阿里3-10重量份、薏苡仁15~30重量份、黄柏8-15重量份、牛膝5-15重量份、苍术10-20重量份、威灵仙5-15重量份、车前子15-30重量份、川芎12-20重量份、珠子草10-20重量份、桂枝8-15重量份、红花5-15重量份、鸡矢藤10-25重量份、丹参12-25重量份、土茯苓15-30重量份、金钱草10-25重量份、五加皮10-20重量份、乳香5-15重量份、千年健8-15重量份、没药5-15重量份、连翘5-15重量份;
所述复合菌包括浓度为1.0×108~2.5×108CFU/mL的酵母菌和浓度为2.0×108~3.2×108CFU/mL的醋酸菌。
2.根据权利要求1所述的治疗痛风病的中药酵素,其特征在于,所述中药原料还包括追地风8~18重量份、延胡索5-15重量份、肾茶8-15重量份。
3.根据权利要求2所述的治疗痛风病的中药酵素,其特征在于,所述东革阿里为红东革阿里、黄东革阿里、黑东革阿里中的一种或两种以上混合。
4.根据权利要求1-3任一项所述的治疗痛风病的中药酵素,其特征在于,所述中药原料包括:东革阿里5-8重量份、薏苡仁20~25重量份、黄柏10-15重量份、牛膝8-12重量份、苍术12-18重量份、威灵仙8-12重量份、车前子18-25重量份、川芎15-18重量份、珠子草12-18重量份、桂枝10-12重量份、红花8-12重量份、鸡矢藤15-20重量份、丹参15-20重量份、土茯苓20-25重量份、金钱草15-20重量份、五加皮12-18重量份、乳香8-12重量份、千年健10-15重量份、没药8-12重量份、连翘8-12重量份、追地风10~15重量份、延胡索8-12重量份、肾茶10-15重量份。
5.根据权利要求2所述的治疗痛风病的中药酵素,其特征在于,所述中药原料包括:红东革阿里5重量份、黑东革阿里5份、薏苡仁22重量份、黄柏12重量份、牛膝10重量份、苍术15重量份、威灵仙10重量份、车前子20重量份、川芎15重量份、珠子草15重量份、桂枝10重量份、红花10重量份、鸡矢藤18重量份、丹参18重量份、土茯苓22重量份、金钱草18重量份、五加皮15重量份、乳香10重量份、千年健12重量份、没药10重量份、连翘10重量份、追地风12重量份、延胡索10重量份、肾茶12重量份。
6.根据权利要求1-4任一项所述的治疗痛风病的中药酵素,其特征在于,所述复合菌还包括浓度为1.2×108~2.0×108CFU/mL乳酸菌。
7.一种如权利要求1所述的治疗痛风病的中药酵素的制备方法,其特征在于,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,然后将每种中药粉末单独用超声萃取,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液;
灭菌步骤:将上述酶解液在灭菌器中进行灭菌处理;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2-3天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1-2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为30-37%,在浓缩后的酶解液接种1.2-2.0%的酵母菌和1.0-1.2%醋酸菌后先在20-25℃温度下摇床发酵,然后在28-30℃温度下静置发酵,得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为15-22%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
8.根据权利要求7所述的制备方法,其特征在于,所述超声萃取步骤中,采用20kHz的低频超声萃取8-12分钟,所述中药粉末与水的料液比为1:(100-400)。
9.根据权利要求7所述的制备方法,其特征在于,所述酶解步骤中,采用的复合酶的加酶量为100-150μg/g,所述复合酶是质量比为1:1:(2-5)的果胶酶、蛋白酶、纤维素酶;酶解的时间为8-12小时,酶解的温度控制在45-52℃,酶解液的pH值为5.5-5.8。
10.一种如权利要求1所述的治疗痛风病的中药酵素的制备方法,其特征在于,包括
超声萃取步骤:按照比例将所述中药原料经过干燥后再分别粉碎得到中药粉末,中药粉末中加水搅拌均匀,然后在每种中药粉末单独用超声萃取,得到中药萃取物;
酶解步骤:将上述得到的每种中药萃取物混合后加入复合酶进行酶解,得到酶解液;
菌种活化和培养步骤:分别用液体培养基溶解酵母菌粉和醋酸菌,振荡使菌体溶解成悬浮液状态,然后将菌液在YDP培养基上进行涂布,酵母菌接种于PDA培养基在30℃恒温培养箱内培养2-3天,经过2次继代培养,菌液待用;醋酸菌接种于基础培养基活化1-2天,经过2次继代培养,菌液待用;乳酸菌接种于MRS培养基在温度37℃下活化l-2天,经过2次继代培养,菌液待用;
接种、发酵步骤:将上述酶解液浓缩至可溶性固形物含量为30-37%,在浓缩后的酶解液接种1.2-2.0%的酵母菌、1.0-1.2%醋酸菌、1.2-1.5%乳酸菌后先在20-25℃温度下摇床发酵,然后在28-30℃温度下静置发酵,最后在35-40℃温度下继续发酵得到发酵液;
真空冷冻干燥:上述发酵液浓缩至重量为15-22%后转入到真空干燥器中进行真空冷冻干燥;得到粉末状的中药酵素。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810024189.6A CN107998313A (zh) | 2018-01-10 | 2018-01-10 | 一种治疗痛风病的中药酵素及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810024189.6A CN107998313A (zh) | 2018-01-10 | 2018-01-10 | 一种治疗痛风病的中药酵素及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107998313A true CN107998313A (zh) | 2018-05-08 |
Family
ID=62050518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810024189.6A Pending CN107998313A (zh) | 2018-01-10 | 2018-01-10 | 一种治疗痛风病的中药酵素及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107998313A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108902949A (zh) * | 2018-07-30 | 2018-11-30 | 山东晨彰生物科技有限公司 | 一种具有预防痛风功能的酵素及其制备方法 |
| CN112971133A (zh) * | 2021-04-19 | 2021-06-18 | 海南云皓生物科技有限公司 | 一种鸡矢藤酵素及其制备方法与在制备抗炎镇痛的产品中的应用 |
| CN114558065A (zh) * | 2022-03-23 | 2022-05-31 | 桂林医学院 | 一种降尿酸的肾茶发酵组合物及其制备方法 |
| CN115010823A (zh) * | 2022-06-16 | 2022-09-06 | 佳木斯大学 | 一种调节肠道菌群的车前子多糖及其制备方法与应用 |
| CN117695359A (zh) * | 2023-11-10 | 2024-03-15 | 成都大学 | 一种四妙丸复方发酵液及其制备方法和应用 |
| CN117695359B (zh) * | 2023-11-10 | 2026-02-17 | 成都大学 | 一种四妙丸复方发酵液及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107125736A (zh) * | 2017-05-04 | 2017-09-05 | 郝之奎 | 一种覆盆子酵素的制备方法 |
-
2018
- 2018-01-10 CN CN201810024189.6A patent/CN107998313A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107125736A (zh) * | 2017-05-04 | 2017-09-05 | 郝之奎 | 一种覆盆子酵素的制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 叶勇等: ""复方中药组方抗痛风的实验研究"", 《浙江中医药大学学报》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108902949A (zh) * | 2018-07-30 | 2018-11-30 | 山东晨彰生物科技有限公司 | 一种具有预防痛风功能的酵素及其制备方法 |
| CN112971133A (zh) * | 2021-04-19 | 2021-06-18 | 海南云皓生物科技有限公司 | 一种鸡矢藤酵素及其制备方法与在制备抗炎镇痛的产品中的应用 |
| CN114558065A (zh) * | 2022-03-23 | 2022-05-31 | 桂林医学院 | 一种降尿酸的肾茶发酵组合物及其制备方法 |
| CN114558065B (zh) * | 2022-03-23 | 2024-03-08 | 桂林医学院 | 一种降尿酸的肾茶发酵组合物及其制备方法 |
| CN115010823A (zh) * | 2022-06-16 | 2022-09-06 | 佳木斯大学 | 一种调节肠道菌群的车前子多糖及其制备方法与应用 |
| CN115010823B (zh) * | 2022-06-16 | 2023-03-24 | 佳木斯大学 | 一种调节肠道菌群的车前子多糖及其制备方法与应用 |
| CN117695359A (zh) * | 2023-11-10 | 2024-03-15 | 成都大学 | 一种四妙丸复方发酵液及其制备方法和应用 |
| CN117695359B (zh) * | 2023-11-10 | 2026-02-17 | 成都大学 | 一种四妙丸复方发酵液及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103689296B (zh) | 妊娠后期和哺乳期的母羊饲料及其制备方法 | |
| CN102940155B (zh) | 一种樱桃谷鸭的雏鸭饲料及其制备方法 | |
| CN102178100B (zh) | 一种低色氨酸杂交鸡饲料及其制备方法 | |
| CN104187172B (zh) | 用于治疗乌龟肠胃炎病的功能性饲料及其制备方法 | |
| CN106310120A (zh) | 一种广普型中药组合物水剂及其制备方法 | |
| CN101836691A (zh) | 一种中草药饲料添加剂 | |
| CN105166544A (zh) | 一种猪配合饲料及其制备方法 | |
| CN107998313A (zh) | 一种治疗痛风病的中药酵素及其制备方法 | |
| CN103652360A (zh) | 用于治疗猪副伤寒的饲料及其制备方法 | |
| CN108338258A (zh) | 一种怀孕母猪用合生素饲料添加剂及制备方法及应用 | |
| CN102100828A (zh) | 一种治疗糖尿病的药物 | |
| CN103301267A (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
| CN104435907A (zh) | 一种用于畜禽催肥的复方发酵型中药及其制备方法 | |
| CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
| CN106860814B (zh) | 一种改善女性尿频、尿失禁的保健食品组合物及其制备方法和应用 | |
| CN104189413A (zh) | 用于治疗乌龟肠胃炎病的药物组合物及其制备方法 | |
| CN104721629B (zh) | 一种治疗小儿缺铁性贫血的中药制剂及制备方法 | |
| CN103099885A (zh) | 具有祛痤疮功能软胶囊及其制备方法 | |
| CN103566312B (zh) | 一种治疗猪食欲不振的中药组合物 | |
| CN102579818A (zh) | 一种藏药组合物及其制备方法与应用 | |
| CN104223062B (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 | |
| CN104258224A (zh) | 一种治疗肺肾阴虚型慢性支气管炎的五味子口服液及其制备方法 | |
| CN105327147A (zh) | 用于治疗猪气喘病的药物组合物及其制备方法 | |
| CN104784491A (zh) | 一种治疗蛋鸡输卵管炎的中药制剂及其制备方法 | |
| CN106344655A (zh) | 一种具有降血糖功效的中药组合物及其制作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180508 |